Sionna Therapeutics (SION) Non-Current Assets (2024 - 2026)

Quarterly results put Non-Current Assets at $84.1 million for Q1 2026, down 12.41% from a year ago — trailing twelve months through Mar 2026 was $340.9 million (changed N/A YoY), and the annual figure for FY2025 was $84.5 million, up 143.2%.

Sionna Therapeutics has reported Non-Current Assets over the past 3 years, most recently at $84.1 million for Q1 2026.

  • Non-Current Assets reached $84.1 million in Q1 2026 per SION's latest filing, down from $84.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $96.0 million in Q1 2025 and bottomed at $34.8 million in Q4 2024.
  • Median Non-Current Assets over the past 3 years was $84.9 million (2025), compared with a mean of $78.6 million.
  • The largest annual shift saw Non-Current Assets surged 143.2% in 2025 before it dropped 12.41% in 2026.
  • Over 3 years, Non-Current Assets stood at $34.8 million in 2024, then skyrocketed by 143.2% to $84.5 million in 2025, then decreased by 0.54% to $84.1 million in 2026.
  • Business Quant data shows Non-Current Assets for SION at $84.1 million in Q1 2026, $84.5 million in Q4 2025, and $86.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 4.56 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - 62,953.78
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 486.60 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - 5.83 Mn
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 14.75 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 22.66 Bn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 910.24 Mn
10 Sionna Therapeutics 1.87 Bn 1.87 Bn - 84.08 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 84.08 Mn
Dec 31, 2025 84.53 Mn
Sep 30, 2025 86.94 Mn
Jun 30, 2025 85.30 Mn
Mar 31, 2025 95.99 Mn
Dec 31, 2024 34.76 Mn